SCHEMBL5906735

SCHEMBL5906735

COC(=O)[C@H](Cc1ccccc1)Nc1cc(-c2ccc(NC(=O)c3ccccc3)cc2)ncn1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 1/20 0.53
LMNA P02545 2/20 0.47
TP53 P04637 1/20 0.47
MAPT P10636 1/20 0.47
THRB P10828 1/20 0.47
ITGB1 P05556 4/20 0.46
ITGA4 P13612 4/20 0.46
ALDH1A1 P00352 2/20 0.45
GLA P06280 1/20 0.45
SMO Q99835 1/20 0.45
IDO1 P14902 1/20 0.45
TDO2 P48775 1/20 0.45
ADORA2A P29274 1/20 0.45
PTPN1 P18031 2/20 0.45
PTPN2 P17706 1/20 0.45
TACR3 P29371 1/20 0.45
ABL1 P00519 1/20 0.44
BCR P11274 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2D6 P10635 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5906731 1.00 ADORA3 (0.53) ADORA3LMNATP53MAPTTHRB
SCHEMBL5906673 0.90 ITGB1 (0.55) ADORA3ITGB1ITGA4ALDH1A1SMO
SCHEMBL5906670 0.90 ITGB1 (0.55) ADORA3ITGB1ITGA4ALDH1A1SMO
SCHEMBL5906650 0.88 CYP1A2 (0.49) ADORA3LMNATP53MAPTTHRB
SCHEMBL5906651 0.88 CYP1A2 (0.49) ADORA3LMNATP53MAPTTHRB
SCHEMBL5906929 0.86 NPR3 (0.51) ADORA3LMNATP53MAPTTHRB
SCHEMBL5906925 0.86 NPR3 (0.51) ADORA3LMNATP53MAPTTHRB
SCHEMBL5906861 0.86 ELANE (0.48) ADORA3LMNATP53MAPTTHRB
SCHEMBL5906697 0.86 TACR3 (0.47) ADORA3LMNATP53MAPTTHRB
SCHEMBL5906841 0.86 TACR3 (0.47) ADORA3LMNATP53MAPTTHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060089371-A1 Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist BAYER HEALTHCARE AG (DE) 2006-04-27 US disclosed
EP-1575919-A1 PHENYL OR HETEROARYL AMINO ALKANE DERIVATIVES AS IP RECEPTOR ANTAGONIST Bayer HealthCare AG (DE) 2005-09-21 EP disclosed
WO-2004043926-A1 PHENYL OR HETEROARYL AMINO ALKANE DERIVATIVES AS IP RECEPTOR ANTAGONIST BAYER HEALTHCARE AG (DE) 2004-05-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060089371-A1 Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist BPHL, HRH4, HRH2 ADORA3 446/4885LMNA 2179/4885TP53 3647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.